1-7 of 7
Devinder S Gill, MD
Close
Sort by
Journal Articles

ZAP-70 Expression Measured by Quantitative PCR (QPCR) As a Prognostic Marker in Chronic Lymphocytic Leukaemia (CLL)

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Raymond H. Banh, MBBS, FRACP, FRCPA, Catherine Cheung, Russell Saal, Lynne Chambers, Tennille Pelly, Devinder S Gill, MD
Journal: Blood
Blood (2011) 118 (21): 4602.
https://doi.org/10.1182/blood.V118.21.4602.4602
Published: 2011
Journal Articles

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Campbell Tiley, MBBS, FRACP, FRCPA, Ilona Cunningham, John Moore, Miles Prince, MD, FRACP, FRCPA, Paul Cannell, MBBS, FRCPA, FRACP, Steve Gibbons, FRCPA, FRACP, MB, CHB, Jill Tate, BSc, MSc, FFSc, Sanjoy Paul, PhD, MSc, Devinder S Gill, MD
Journal: Blood
Blood (2011) 118 (21): 3973.
https://doi.org/10.1182/blood.V118.21.3973.3973
Published: 2011
Journal Articles

Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,

Maher K Gandhi, PhD, FRACP, FRCPath, FRCP, Mark S. Hertzberg, MD, PhD, Erica Han, John F. Seymour, MD, PhD, Rodney Hicks, MB BS, MD, FRACP, Devinder S Gill, MD, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Pauline Crooks, Kristen Radford, PhD, Frank Vari, Phd
Journal: Blood
Blood (2011) 118 (21): 3673.
https://doi.org/10.1182/blood.V118.21.3673.3673
Published: 2011
Journal Articles

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Linda Shen, FRCPA, Erica Han, Jamie P Nourse, PhD, Rod Lea, PhD, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Devinder S Gill, MD, Maher K Gandhi, PhD, FRACP, FRCPath, FRCP
Journal: Blood
Blood (2011) 118 (21): 1585.
https://doi.org/10.1182/blood.V118.21.1585.1585
Published: 2011
Journal Articles

Genome-Wide Analysis of Genetic Alterations In Acute Myeloid Leukaemia (Massively parallel, high-throughput, paired-end DNA sequencing and genotyping of an AML genome).

James X Gray, MD, PhD, Paul J Leo, PhD, Pamela Mukhopadhyay, PhD, Evgeny A Glazov, PhD, Patrick Danoy, PhD, Marina Donskoi, BSc, Anna Brown, PhD, Ian D. Lewis, MBBS, PhD, Richard J D'Andrea, PhD, Matthew A Brown, MBBS, MD, Paula Marlton, MBBS, Devinder S Gill, MD, Thomas Gonda, PhD
Journal: Blood
Blood (2010) 116 (21): 1690.
https://doi.org/10.1182/blood.V116.21.1690.1690
Published: 2010
Journal Articles

The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MD, William E. P. Renwick, MBBS, FRACP, Melanie L Sulda, BSc, Ph.D, O. Giles Best, BSc, PhD, Bryone J Kuss, PhD, FRCPA, FRACP, MBBS, John F Seymour, MD, FRACP
Journal: Blood
Blood (2010) 116 (21): 699.
https://doi.org/10.1182/blood.V116.21.699.699
Published: 2010
Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Michael Pfreundschuh, MD, Evelyn Kuhnt, Lorenz Trümper, MD, Anders Osterborg, MD, PhD, Marek Trneny, MD, Lois Shepherd, MD, Devinder S Gill, MD, Jan Walewski, MD, Ruth Pettengell, FRACP, PhD, Ulrich Jäger, MD, Pier Luigi Zinzani, MD, PhD, Ofer Shpilberg, MD, MPH, Stein Kvaloy, MD, Mads Hansen, MD, Rolf Stahel, MD, Noel Milpied, MD, Armando Lopez-Guillermo, MD, Sandra Grass, MD, Niels Murawski, MD, Viola Pöschel, Markus Löffler
Journal: Blood
Blood (2010) 116 (21): 111.
https://doi.org/10.1182/blood.V116.21.111.111
Published: 2010